Actinium Pharmaceuticals, Inc. (ATNM) stock
ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.08−0.27 (-20.00%)
Close on Nov 18, 2026Market cap $33.96MP/E 3.0Yield –
Actinium Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Actinium Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $9.56M. For fiscal 2025 it was -$36.25M. The highest annual figure on record is -$26.05K in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$36.25M | – |
| FY2024 | Dec 31, 2024 | -$42.12M | – |
| FY2023 | Dec 31, 2023 | -$51.92M | – |
| FY2022 | Dec 31, 2022 | -$34.10M | – |
| FY2021 | Dec 31, 2021 | -$24.96M | – |
| FY2020 | Dec 31, 2020 | -$22.39M | – |
| FY2019 | Dec 31, 2019 | -$22.07M | – |
| FY2018 | Dec 31, 2018 | -$23.83M | – |
| FY2017 | Dec 31, 2017 | -$26.91M | – |
| FY2016 | Dec 31, 2016 | -$26.85M | – |
| FY2015 | Dec 31, 2015 | -$24.83M | – |
| FY2014 | Dec 31, 2014 | -$22.48M | – |
| FY2013 | Dec 31, 2013 | -$6.59M | – |
| FY2012 | Dec 31, 2012 | -$7.95M | – |
| FY2011 | Dec 31, 2011 | -$3.28M | – |
| FY2010 | Dec 31, 2010 | -$26.05K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $27.57M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.41M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.69M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.64M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.51M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.42M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.34M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.35M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.64M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.29M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.80M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.85M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.47M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.08M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.44M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.61M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.66M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.68M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.63M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.65M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.09M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.70M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.20M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.91M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.35M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.21M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.70M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.20M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.81M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.83M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.10M | – |
See a number that looks wrong?